

# Information Disclosure | FY2023 Archive

## I Appropriate Information Disclosure

In accordance with the policy stated in our Declaration of Conduct, we at Sumitomo Pharma proactively disclose information to the public and, under the recognition of the importance of transparency in earning society's trust, we work to disclose our corporate information in a timely, appropriate and fair manner to our various stakeholders.

We promptly disclose information for which timely disclosure is required, such as determined facts, occurring facts, and account settlement-related information provided for in the Tokyo Stock Exchange's various rules concerning timely disclosure, through the Timely Disclosure Network (TDnet), the notification system provided by the stock exchange, as well as on our website. We also disclose information in English.

With regard to information for which timely disclosure is not required, we actively disclose information needed for stakeholders, including shareholders, to understand Sumitomo Pharma properly through such means as press releases and our corporate website.

We disclose corporate information pursuant to the Basic Stance on Information Disclosure (disclosure policy) and the Information Disclosure Code that prescribes such matters as standards and procedures for disclosing information. For our basic stance on and standards for information disclosure, please see "[Stance on Information Disclosure](#)" in Investor Relations.